OakChart

Galectin Therapeutics Inc

GALTHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:02 AM ET

3.41+0.03 (0.80%)
2026-11-11 16:02 CET
Market cap
340.87 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-28.03 USD m
Free cash flow, TTM
-15.89 USD m
EPS diluted, TTM
-0.43
P/E
-
Compare

Price

GALT against its 20, 50 and 200-day averages
2050200earnings
2.003.004.005.003.2M6.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GALTclose 3.4120-day 3.3850-day 3.70200-day 3.213.41

52.2% under 7.13 on 17 Dec 2025. Last 15 sessions, 27.6% high to low

Profile

GALT
52-week range, 27% of the way up
2.037.13

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

IndexRUT
Employees9
IPOSep 04, 2002
Beta0.50
ATR, 14d0.26
Rel volume0.28
Short float18.82%
Insider own52.71%
Inst own15.56%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap343.61M
Enterprise Value470.30M
Income-28.03M
Sales0.00M
Book/sh-2.10
Cash/sh0.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees9
IPOSep 04, 2002

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C25.89
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.10
Current Ratio0.10
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.43
EPS next Y-0.23
EPS next Q-0.05
EPS this Y37.50%
EPS next Y23.33%
EPS next 5Y-
EPS past 3/5Y9.53% -3.21%
Sales past 3/5Y- -
EPS Y/Y TTM33.25%
Sales Y/Y TTM-
EPS Q/Q-16.57%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.-55.56% -

Ownership

Insider Own52.71%
Insider Trans-0.20%
Inst Own15.56%
Inst Trans6.78%
ROA-183.01%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.70%
SMA50-8.03%
SMA2006.02%
Trades-

Technical

Shs Outstand66.31M
Shs Float47.69M
Short Float18.82%
Short Ratio33.49
Short Interest8.98M
52W High7.13 -52.21%
52W Low2.03 68.26%
Volatility11.58% 7.90%
ATR (14)0.26
RSI (14)48.28
Beta0.50
Rel Volume0.28
Avg Volume268.04K
Volume9,473

Performance

Perf Week-1.81%
Perf Month-7.66%
Perf Quarter-3.48%
Perf Half Y52.79%
Perf YTD-18.10%
Perf Year-38.05%
Perf 3Y62.25%
Perf 5Y18.31%
Perf 10Y274.42%
Recom1.00
Target Price11.00
Prev Close3.38
Price3.41
Change %0.80%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 17, 2025ResumedHH.C. WainwrightBuy$6+76.1%
Aug 13, 2020ReiteratedHH.C. WainwrightBuy$9 → $12+252.2%
Feb 13, 2019InitiatedBB. Riley FBRBuy$11+222.8%
Dec 07, 2017ReiteratedHH.C. WainwrightBuy$6 → $10+193.5%
Nov 28, 2017ReiteratedHH.C. WainwrightBuy$3.50 → $6+76.1%
Oct 19, 2017InitiatedRROTH CapitalBuy
Mar 30, 2017UpgradeHH.C. WainwrightNeutral → Buy$3.50+2.7%
Oct 03, 2016DowngradeFFBR & Co.Outperform → Mkt Perform$12 → $2-41.3%
Sep 29, 2016DowngradeHH.C. WainwrightBuy → Neutral$1.50-56.0%
Sep 28, 2016DowngradeRROTH CapitalBuy → Sell

Peers

Mkt cap
TickerCompanyMkt cap
IVAInventiva ADR920.53M
SGMTSagimet Biosciences Inc774.67M
ALTAltimmune Inc373.47M
MDGLMadrigal Pharmaceuticals Inc10.13B
GYREGyre Therapeutics Inc499.34M
VKTXViking Therapeutics Inc3.68B
MIRMMirum Pharmaceuticals Inc6.18B
CORTCorcept Therapeutics Inc8.22B
LPCNLipocine Inc17.78M
NVONovo Nordisk ADR134.62B

Insider trading

latest 14 of 77
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Uihlein Richard EDirectorJul 31 '26Option Exercise3.0834,376,167105,806,98044,713,843Aug 04 07:52 AM
Jamil KhurramChief Medical OfficerJul 14 '26Option Exercise3.0416,25049,40016,250Jul 16 05:39 PM
Jamil KhurramChief Medical OfficerJul 14 '26Sale5.1316,25083,2840Jul 16 05:39 PM
Shlevin Harold H.DirectorJun 29 '26Option Exercise1.2322,26827,39028,768Jun 30 07:24 PM
Shlevin Harold H.DirectorJun 26 '26Option Exercise1.237,7329,51014,232Jun 30 07:24 PM
Shlevin Harold H.DirectorJun 29 '26Sale5.0422,268112,2316,500Jun 30 07:24 PM
Shlevin Harold H.DirectorJun 26 '26Sale5.007,73238,6606,500Jun 30 07:24 PM
Jamil KhurramChief Medical OfficerJun 29 '26Option Exercise2.5047,467118,66847,467Jun 30 07:23 PM
Jamil KhurramChief Medical OfficerJun 26 '26Option Exercise2.374,57010,8142,533Jun 30 07:23 PM
Jamil KhurramChief Medical OfficerJun 29 '26Sale5.0447,467239,2340Jun 30 07:23 PM
Jamil KhurramChief Medical OfficerJun 26 '26Sale5.004,57022,8500Jun 30 07:23 PM
Harold ShlevinDirectorJun 29 '26Proposed Sale5.0422,268112,212Jun 29 04:09 PM
Jamil KhurramOfficerJun 26 '26Proposed Sale5.0068,287341,435Jun 26 06:09 PM
HAROLD SHLEVINDIRECTORJun 26 '26Proposed Sale5.007,73238,680Jun 26 04:15 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B
MEDXHorizon Kinetics Medical ETFAUM: 17.88M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 206
  • Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026 (GlobeNewswire) -13.98%
  • Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 (GlobeNewswire)
  • Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet (GlobeNewswire)
  • Loading…
  • GALT Stock Surges 22% On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial (Stocktwits) +11.43%
  • Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension (GlobeNewswire)
  • Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis (GlobeNewswire)
  • Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update (GlobeNewswire) -7.66%
  • Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology (GlobeNewswire) +5.24%
  • Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.56%
  • Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. (GlobeNewswire)
  • Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET (GlobeNewswire) -5.10%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.140-0.090-0.1400.000.001
2026Q12026-05-15-0.080-0.060-0.0770.000.001
2025Q42026-03-31-0.080-0.100-0.0850.000.001
2025Q32025-11-14-0.130-0.110-0.1280.000.001
2025Q22025-08-14-0.120-0.160-0.1200.000.001
2025Q12025-05-15-0.150-0.200-0.1520.00-1
2024Q42025-03-31-0.190-0.160-0.1920.00-1
2024Q32024-11-14-0.180-0.200-0.1800.00-1
2024Q22024-08-13-0.200-0.160-0.2000.00-1
2024Q12024-05-15-0.190-0.160-0.1860.00-1
2023Q42024-03-29-0.160-0.100-0.163--1
2023Q32023-11-13-0.240-0.100-0.235--1
2023Q22023-08-14-0.150-0.140-0.154--1
2023Q12023-05-15-0.190-0.140-0.1940.000.001
2022Q42023-03-30-0.180-0.170-0.1800.000.001
2022Q32022-11-14-0.140-0.200-0.1450.00-1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-0.380-0.365-0.3820.000.00
2019FY-0.390-0.350-0.2600.000.00
2020FY-0.410-0.330-0.414--
2021FY-0.520-0.450-0.525--
2022FY-0.650-0.650-0.655--
2023FY-0.740-0.480-0.7450.00-
2024FY-0.760-0.730-0.7580.00-
2025FY-0.480-0.490-0.4800.000.00
2026FY--0.300--0.00
2027FY--0.230--0.00
2028FY--1.060---
2029FY--0.910--23.10

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-141000.000.000.00
2026Q3S2026-05-151000.000.000.00
2026Q3S2026-03-311000.000.000.00
2026Q3E2026-10-28100-0.05-0.05-0.05
2026Q3E2026-08-14110-0.05-0.05-0.05
2026Q3E2026-07-29100-0.10-0.10-0.10
2026Q3E2026-05-15101-0.10-0.10-0.10
2026Q3E2026-03-31100-0.09-0.09-0.09
2026Q2S2026-05-151000.000.000.00
2026Q2S2026-03-311000.000.000.00
2026Q2E2026-07-29100-0.09-0.09-0.09
2026Q2E2026-05-15101-0.09-0.09-0.09
2026Q2E2026-03-31100-0.07-0.07-0.07
2026Q1S2026-03-311000.000.000.00

Estimate history

EPS, annual-0.49-0.382-0.26-0.414-0.525-0.655-0.745-0.758-0.485-0.4297
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.2-0.18-0.192-0.152-0.12-0.128-0.085-0.077-0.139
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual35.78941.19156.89557.07759.34159.42661.85363.15765.20266.312
Period201720182019202020212022202320242025MRQ
Shares, quarterly62.27862.30863.15763.29264.0664.47365.20265.85766.312
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.060.050.040.030.030.040.040.040.00
Gross Profit-0.06-0.05-0.04-0.03-0.03-0.04-0.04-0.040.00
Selling, General and Administrative Excl. Other15.5620.0342.4038.0438.3230.1423.4113.4013.60
Research and Development8.9114.2936.5732.1331.7423.8217.987.476.47
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-15.62-20.09-42.43-38.07-38.35-30.18-23.44-13.44-13.60
Interest Expense7.757.335.542.791.030.490.090.090.34
Unusual Expense4.603.55-0.590.43-0.56-0.140.00--
Net Income Before Taxes-27.84-30.84-47.05-41.07-38.78-30.53-23.46-13.29-13.90
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-27.84-30.84-47.05-41.07-38.78-30.53-23.46-13.29-13.90
Net Income From Continuing Operations-27.84-30.84-47.05-41.07-38.78-30.53-23.46-13.29-13.90
Net Income-28.03-30.97-47.20-41.19-38.87-30.70-23.60-13.56-15.05
EPS (Recurring)-0.38-0.45-0.76-0.74-0.66-0.53-0.41-0.26-0.38
EPS (Basic, Before Extraordinaries)-0.43-0.48-0.76-0.74-0.65-0.52-0.41-0.26-0.38
EPS (Diluted)-0.43-0.48-0.76-0.74-0.65-0.52-0.41-0.26-0.38
EBITDA-15.56-20.03-42.40-38.04-38.32-30.14-23.41-13.40-13.60
Non-Operating Income (Expense)0.130.130.340.230.050.000.070.230.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.431.662.452.262.872.081.801.684.45
Shares Outstanding66.3165.2063.1661.8559.4359.3457.0856.8941.19
Market Capitalization340.87340.8780.38102.6767.15122.84127.85162.69141.10

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.010.040.000.000.010.010.01
Gross Profit-0.00-0.01-0.040.00-0.00-0.01-0.01-0.01
Selling, General and Administrative Excl. Other3.984.073.324.204.627.8912.429.06
Research and Development2.132.231.932.613.266.4911.117.59
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.98-4.08-3.37-4.20-4.62-7.90-12.43-9.07
Interest Expense2.001.991.941.821.831.741.731.49
Unusual Expense3.15-0.980.222.211.100.03-2.100.75
Net Income Before Taxes-9.11-5.05-5.50-8.18-7.52-9.63-11.97-11.22
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-9.11-5.05-5.50-8.18-7.52-9.63-11.97-11.22
Net Income From Continuing Operations-9.11-5.05-5.50-8.18-7.52-9.63-11.97-11.22
Net Income-9.18-5.07-5.56-8.22-7.58-9.61-12.03-11.24
EPS (Recurring)-0.11-0.09-0.08-0.10-0.11-0.15-0.22-0.17
EPS (Basic, Before Extraordinaries)-0.14-0.08-0.09-0.13-0.12-0.15-0.19-0.18
EPS (Diluted)-0.14-0.08-0.09-0.13-0.12-0.15-0.19-0.18
EBITDA-3.98-4.07-3.32-4.20-4.62-7.89-12.42-9.06
Non-Operating Income (Expense)0.030.040.030.040.030.040.080.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.960.780.190.500.500.471.100.52
Shares Outstanding66.3165.8665.2064.4764.0663.2963.1662.31
Market Capitalization340.87179.90268.23271.30133.5576.0280.38171.26

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments17.7215.1225.6618.5939.6527.1447.488.253.06
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.722.132.051.962.172.320.730.580.76
Total Current Assets19.4417.2527.7120.5541.8229.4648.218.833.82
Net Property, Plant & Equipment0.020.020.050.090.000.050.080.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets-------0.000.00
Other Assets0.070.230.440.650.010.090.170.170.34
Total Assets19.5317.5028.2021.2941.8329.6048.479.014.16
Short Term Debt Incl. Current Port. of LT Debt0.0221.140.050.040.010.040.040.000.00
Accounts Payable3.255.666.433.891.801.291.660.300.61
Other Current Liabilities4.768.629.209.087.224.061.121.812.36
Total Current Liabilities8.0335.4115.6813.019.035.402.822.112.97
Long Term Debt133.7485.1171.7639.8929.050.010.050.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities3.960.051.000.571.130.000.000.000.00
Total Liabilities145.73120.5688.4453.4839.215.412.872.112.97
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value2.212.222.222.232.252.252.268.948.96
Common Equity-128.41-105.29-62.46-34.430.3721.9443.34-2.04-7.77
Total Shareholders Equity-126.19-103.07-60.24-32.192.6224.1945.596.901.19
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-126.19-103.07-60.24-32.192.6224.1945.596.901.19
Total Liabilities & Stockholders Equity19.5317.5028.2021.2941.8329.6048.479.014.16
Book Value Per Share-1.97-1.67-1.01-0.580.010.380.76-0.05-0.22
Tangible Book Value Per Share-1.97-1.67-1.01-0.580.010.380.76-0.05-0.22
Full-Time Employees915141296767
Price to Book Ratio-1.61-0.85-1.93-2.73335.495.833.75-69.13-18.92
Return on Assets-166.56-205.92-165.97-122.88-85.48-60.12-46.26-211.13-162.71
Return on Equity-----227.74-67.25-50.65-343.59-245.84
Return on Invested Capital-408.97--356.48-503.58-96.41-96.96-29.12-201.51-1,360.85
Quick Ratio2.420.491.771.584.635.4617.104.191.29
Current Ratio2.420.491.771.584.635.4617.104.191.29

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-27.84-30.84-47.05-41.07-38.78-30.53-23.46-13.29-13.90
Depreciation0.060.050.040.030.030.040.040.040.00
Other Funds (Non Cash)7.656.302.963.392.722.431.891.774.79
Funds from Operations-20.14-24.48-44.05-37.64-36.02-28.06-21.54-11.49-9.11
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.250.612.284.684.973.750.940.64-1.07
Cash from Operating Activities-15.89-23.88-41.77-32.97-31.06-24.31-20.60-10.85-10.18
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.00-0.390.00
Change in Capital Stock5.395.471.2340.0310.006.810.2650.4715.38
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.395.471.2340.0310.006.810.2650.4715.38
Proceedsfrom Stock Options3.233.230.0030.0010.000.000.000.000.00
Issuance or Reduction of Debt, Net10.0021.0030.000.000.0030.000.000.000.00
Change in Long Term Debt10.0021.0030.000.000.0030.000.000.000.00
Issuance of Long Term Debt10.0021.0030.000.000.0030.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities15.3926.4831.2340.0310.0036.810.2650.0815.38
Net Change in Cash-0.502.60-10.547.07-21.0612.51-20.3439.235.20
Free Cash Flow-15.89-23.88-41.77-32.97-31.06-24.31-20.60-10.85-10.18
Preferred Dividends (Cash Flow)------0.00-0.39-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments13.2714.1117.7211.5313.777.43
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.391.581.721.201.661.85
Total Current Assets14.6615.6919.4412.7315.439.29
Net Property, Plant & Equipment0.120.010.020.000.050.07
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.050.060.070.140.120.18
Total Assets14.8315.7619.5312.8715.609.53
Short Term Debt Incl. Current Port. of LT Debt137.760.010.02122.310.0597.17
Accounts Payable3.733.123.255.395.876.53
Other Current Liabilities10.134.184.768.744.867.13
Total Current Liabilities151.627.318.03136.4410.77110.84
Long Term Debt0.00135.71133.740.00120.4610.81
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.062.983.960.001.540.14
Total Liabilities151.68146.00145.73136.44132.77121.79
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value2.202.202.212.212.212.22
Common Equity-139.06-132.44-128.41-125.79-119.38-114.48
Total Shareholders Equity-136.85-130.24-126.19-123.58-117.17-112.26
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-136.85-130.24-126.19-123.58-117.17-112.26
Total Liabilities & Stockholders Equity14.8315.7619.5312.8715.609.53
Book Value Per Share-2.10-2.01-1.97-1.95-1.86-1.81
Tangible Book Value Per Share-2.10-2.01-1.97-1.95-1.86-1.81
Full-Time Employees--9---
Price to Book Ratio-1.61-1.42-2.13-2.27-1.17-0.73
Return on Assets-183.01-207.62-166.56-178.33-186.51-255.18
Return on Invested Capital--92.20-72.94--228.53-
Quick Ratio0.102.152.420.091.430.08
Current Ratio0.102.152.420.091.430.08

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-9.11-5.05-5.50-8.18-7.52-9.63
Depreciation0.000.010.040.000.000.01
Other Funds (Non Cash)4.28-0.140.602.921.950.84
Funds from Operations-4.83-5.17-4.86-5.27-5.57-8.78
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.391.31-1.181.73-1.031.09
Cash from Operating Activities-2.44-3.87-6.04-3.54-6.60-7.69
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock1.600.262.241.301.940.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.600.262.241.301.940.00
Proceedsfrom Stock Options0.000.003.230.000.000.00
Issuance or Reduction of Debt, Net0.000.0010.000.0011.000.00
Change in Long Term Debt0.000.0010.000.0011.000.00
Issuance of Long Term Debt0.000.0010.000.0011.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.600.2612.241.3012.940.00
Net Change in Cash-0.84-3.616.20-2.256.34-7.69
Free Cash Flow-2.44-3.87-6.04-3.54-6.60-7.69

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.82%9.0M47.7M292.87K
2026-10-1519.15%9.1M47.7M322.33K
2026-09-3019.36%9.2M47.6M407.15K
2026-09-1519.63%9.3M47.6M659.48K
2026-08-3119.09%9.1M47.6M634.33K
2026-08-1418.93%9.0M47.6M658.26K
2026-07-3112.10%8.7M71.9M646.32K
2026-07-1518.10%8.5M46.9M638.46K
2026-06-3019.12%9.0M46.9M574.59K
2026-06-1516.76%7.9M46.9M316.86K
2026-05-2916.33%7.7M46.9M354.47K
2026-05-1515.68%7.4M46.9M328.41K
2026-04-3015.89%7.4M46.5M317.29K
2026-04-1516.04%7.5M46.5M320.67K
2026-03-3114.62%6.8M46.5M339.37K
2026-03-1314.42%6.6M45.6M464.54K
2026-02-2711.35%5.2M45.6M483.95K
2026-02-1311.18%5.1M45.6M498.98K
2026-01-3010.53%4.8M45.6M528.15K
2026-01-1510.42%4.7M45.6M528.22K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.201.951.518.7182.000.000.895-0.0090.001
call5.000.000.050.072.1736340.000.179-0.0160.001
call7.500.000.050.012.9561,0350.000.081-0.0130.001
put2.500.000.050.052.0421010.00-0.155-0.0140.001
put5.000.002.702.237.00525.000.00-0.885-0.0100.001
put7.503.204.900.006.9860.000.00-0.919-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-13ARSAnnual report to security holders. 2025-12-31SEC
2026-10-13DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-13DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-03SEC
2026-10-02PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-03SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-04SCHEDULE 13D/ASEC
2026-08-048-KCurrent report2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-10EFFECTEffectiveness filing by commission orderSEC
2026-04-08CORRESPSEC
2026-04-06UPLOADUpload SubmissionSEC
2026-03-31S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-03-318-KCurrent report2026-03-31SEC
2026-03-3110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-178-KCurrent report2026-03-12SEC
2026-03-174Statement of changes in beneficial ownership of securities2026-03-12SEC
2026-03-173Initial statement of beneficial ownership of securities2026-03-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070083.28K1
2026-0600436.70K5
2026-05001.76K1
2026-040000
2026-030000
2026-02810100
2026-0100786.92K9
2025-1224.74K32.69M11
2025-11001.83M14

Institutional holders

Manager% owned
BlackRock, Inc.4.54%
VANGUARD CAPITAL MANAGEMENT LLC3.29%
OSAIC HOLDINGS, INC.1.83%
MARSHALL WACE, LLP1.26%
GEODE CAPITAL MANAGEMENT, LLC1.24%
Wealthspire Advisors, LLC1.10%
STATE STREET CORP0.86%
NORTHERN TRUST CORP0.59%
VANGUARD FIDUCIARY TRUST CO0.56%
VANGUARD PORTFOLIO MANAGEMENT LLC0.50%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.31%
iShares Russell 2000 ETF1.44%
VANGUARD EXTENDED MARKET INDEX FUND0.90%
Fidelity Small Cap Index Fund0.79%
iShares Russell 2000 Growth ETF0.47%
VANGUARD RUSSELL 2000 INDEX FUND0.27%
Fidelity Extended Market Index Fund0.26%
iShares Micro-Cap ETF0.24%
Schwab Small-Cap Index Fund0.18%
iShares Russell 2000 Value ETF0.17%

OakChart. GALT. Cached 15 minutes.